Pyxis Oncology Inc (NAS:PYXS)
$ 3.645 -0.005 (-0.14%) Market Cap: 214.65 Mil Enterprise Value: 77.81 Mil PE Ratio: 0 PB Ratio: 1.16 GF Score: 20/100

Pyxis Oncology Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 08:00PM GMT
Release Date Price: $3.08 (-4.64%)
Eun Yang
Jefferies - Analyst

Presenting from Pyxis is Lara Sullivan, CEO of the company. And then at the end of the presentation, we'll have a Q&A for remaining five minutes or so. Thank you. Lara?

Lara Sullivan
Pyxis Oncology, Inc. - President & CEO

All right. Thank you. Thanks, Eun. Let me just make sure I know how this thing works. Yes. Okay, terrific.

We appreciate the opportunity to be here and to participate in the Jeffries Healthcare Conference today. As Eun mentioned, my name is Lara Sullivan. I'm the CEO of Pyxis Oncology. Joining me today are Pam Connealy, our CFO and COO; Jan Pinkas, our Chief Scientific Officer; and Xiaodong Yang, Founder and CEO of Apexigen.

Please note, today's presentation includes forward-looking statements. We encourage you to review these, which are available on our website.

Oops. Okay.

So Pyxis Oncology is focused on advancing next-generation therapeutics to address difficult-to-treat tumors. We are a multi-modality, multi-asset clinical-stage company currently focused on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot